and lack of correlative laboratory data. While the sample size was small, the authors noted that given the rarity of patients with CNS myeloma involvement who successfully receive CAR T-cell ...

Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at ...

Dr. Clark went on to explain to Hart that there was a significant therapeutic advancement in 2017 for the treatment of blood cancers like multiple myeloma with the FDA approval of what is known as ...

“Multiple myeloma is a type of cancer that affects plasma ... from a patient [with a specialized process] and send them to a lab where they are genetically modified to recognize cancer cells ...

A multi-peptide neoantigen cancer vaccine using relatively few antigens induced a strong immune response across multiple ...

CRISPR technique can target single genes essential for cancer cell survival, toppling the whole structure, says nanomedicine ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer ...

AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion (€916.5 million) to ...

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...